ライフサイエンスコーパス: L-leucine

1 ), and helical, hydrophobic segments of poly(l-leucine).

2 isolates produced acetone in the presence of L-leucine.

3 approximately 0.61 mol of acetone per mol of L-leucine.

4 ain amino acids, L-isoleucine, L-valine, and L-leucine.

5 the production of alpha-ketoisocaproate from L-leucine.

6 ject to slow-onset, allosteric inhibition by l-leucine.

7 or the improvement in anemia associated with L-leucine.

8 in response to treatment with the amino acid L-leucine.

9 nobicyclo[2.2.1]heptane-2-carboxylic acid or l-leucine.

10 itivity to the inhibitors L-homoarginine and L-leucine.

11 hain amino acids L-isoleucine, L-valine, and L-leucine.

12 ort was monitored by measuring the uptake of L-leucine.

13 )-pyridine], the DGL inhibitor THL [N-formyl-l-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]meth

14 e-1-yl) amino acid (amino acid=L-valine (1), L-leucine (2), L-isoleucine (3), L-tryptophan (4), L-phe

15 Rps14-deficient embryos with the amino acid L-leucine, a known activator of mRNA translation.

16 Treatment of cells with lactulosyl-l-leucine, a synthetic T antigen antagonist that targets

17 beta-alanine act as structure-breaker, while L-leucine acts as structure-maker both in water and in a

18 ddition to catabolite repression by glucose, l-leucine acts by inhibiting the binding of Lrp to the p

19 -norlaudanosine with 1 equiv of (-)-N-acetyl-l-leucine afforded the leucinate salt (+)-13 (99:1 dr).

20 xidation, N-oxalylglycine, L-pipecolic acid, L-leucine, alpha-ketoglutarate, glyoxylic acid, and L-or

21 l-Leucine aminopeptidases (LAPs) are implicated in the p

22 (alpha-ketoglutarate, ammonia, and NADH) and L-leucine (an activator of glutamate dehydrogenase) in t

23 oxylic acid (anti-(18)F-FACBC)is a synthetic l-leucine analog that has excellent in vitro uptake with

24 alkaline pH and exhibits increased rates of l-leucine and 3,3'-dihexyloxacarbocyanine iodide uptake,

25 iniPERM bioreactor in the presence of [U-14C]L-leucine and [U-14C]D-glucose.

26 n domains (A1-PCP1), specifically adenylates l-leucine and d-leucine in a 6:1 ratio, and it can be co

27 structure of two protected amino acids, FMOC-l-leucine and FMOC-l-valine, and a dipeptide, N-acetyl-l

28 it is derived from acetate, L-phenylalanine, L-leucine and L-cysteine.

29 present study we show that NMB0573 binds to l-leucine and l-methionine and have solved the structure

30 d transporter was examined through uptake of L-leucine and L-phenylalanine and provided Km and Vmax v

31 N-Palmitoyl-l-leucine and N-palmitoyl-l-methionine were found to hav

32 Branched-chain amino acids L-isoleucine, L-leucine, and L-valine (ILV) activate CodY both in vivo

33 motactic responses to L-aspartate, L-serine, L-leucine, and Ni(2+) of WT and chemotactic-mutant strai

34 A series of L-leucine aniline analogues were synthesized that contai

35 Furthermore, the therapeutic response to L-leucine appeared specific for Rps19-deficient hematopo

36 l-tyrosine, l-tryptophan, l-methionine, and l-leucine, are converted to the corresponding alpha-hydr

37 hisms at FcgammaRIIIA-48: leucine/leucine (L/L), leucine/arginine (L/R), and leucine/histidine (L/H).

38 individual peaks, we identified N-palmitoyl-l-leucine as a new splicing inhibitor that blocks a late

39 the rationale for ongoing clinical trials of L-leucine as a therapeutic agent for DBA, and potentiall

40 upports the rationale for clinical trials of L-leucine as a therapeutic agent for DBA.

41 henylalanine, and N-(1-deoxy-D-fructos-1-yl)-L-leucine as the most effective inhibitors of colony for

42 rientation of the isopropyl methyl groups of l-leucine at the air-water interface.

43 otic mobilities of the enzyme and substrate, L-leucine beta-naphthylamide, allowed for efficient mixi

44 ter dipeptide surfactant poly(sodium undecyl-L-leucine-beta-alanine) (poly L-SULbetaA).

45 y signal transmitted to the active site upon l-leucine binding in the regulatory domain, a distance o

46 dy conformational changes to the enzyme upon l-leucine binding.

47 This is the first committed step in l-leucine biosynthesis.

48 s well as the poly(L-glutamatic acid)-b-poly(L-leucine) block copolypeptide, E60L20.

49 ssembly of a series of poly(L-lysine)-b-poly(L-leucine) block copolypeptides, KxLy, where x ranged fr

50 pholine)carbonyl-beta-(1-naphthyl)-L-alanine-L-leucine boronic acid (MLN-273), an analogue of the ant

51 up of activating amino acids is dominated by l-leucine but also includes l-methionine, l-isoleucine,

52 variants that have significant affinity for l-leucine but lack biphasic inhibition kinetics.

53 L since in the presence of BCH inhibition by L-leucine but not by L-lysine is sodium dependent.

54 L-Leucine, but not D-leucine, was converted to acetone w

55 ased maternal-fetal transfer of L-serine and L-leucine, but not glycine, following boluses of specifi

56 roate, which is reductively aminated back to L-leucine by leucine dehydrogenase in the presence of am

57 zed as follows: whole-cell biocatalyst 0.8 g/L, leucine concentration 13.1 g/L, temperature 35 degree

58 table substrates of glutamate dehydrogenase, L-leucine dehydrogenase, L-phenylalanine dehydrogenase,

59 recombinant ALD1 transaminates l-methionine, l-leucine, diaminopimelate, and several other amino acid

60 ment of mice with N-(1-deoxy-D-fructos-1-yl)-L-leucine did not have significant antimetastatic effect

61 L-leucine plus L-isoleucine; (f) L-isoleucyl-L-leucine dipeptide; (g) L-leucyl-L-isoleucine dipeptide

62 (a) control; (b) WPH; (c) L-isoleucine; (d) L-leucine; (e) L-leucine plus L-isoleucine; (f) L-isoleu

63 of L-glutamine out of cells and transport of L-leucine/EAA into cells.

64 bitor, and N-(9-fluorenyl-methyloxycarbonyl)-L-leucine (F-L-Leu), a peroxisome proliferator-activated

65 Templates containing D- and L-leucines formed only a single H-bond.

66 seven of those polar metabolites (L-serine, L-leucine, glucose, fructose, myo-inositol, citric acid

67 ght individual amino acids--L-phenylalanine, L-leucine, glycine, L-lysine, L-arginine, L-cysteine, L-

68 no acid glycine, i.e., poly sodium N-undecyl L-leucine-glycine (poly L-SULG) and poly sodium N-undecy

69 t total synthesis of flutimide starting from L-leucine has been described.

70 d viscosities of L-glycine, beta-alanine and L-leucine have been determined in water and in aqueous s

71 the mTOR pathway, and this is accentuated by L-leucine in both Rps19 and Rps14 morphants.

72 LLKLLLLKLLLLK (KL4), in which K = lysine and L = leucine, in an aqueous dispersion of phospholipids (

73 h human chorionic gonadotropin secretion and L-leucine influx through system L were suppressed.

74 410F mutant form of MtIPMS is insensitive to l-leucine inhibition, suggesting that this residue has c

75 had wide-ranging effects on the kinetics of l-leucine inhibition, with some modest effects on the ki

76 3H-labeled FDG, thymidine, L-methionine and L-leucine into the cells was determined in the presence

77 A surprising discovery was that L-leucine is sensed by Tar as an attractant at low conce

78 ET tracers (FDG, thymidine, L-methionine and L-leucine) is affected by acute or chronic hyperglycemia

79 l-L-valine (L-SUV), and sodium N-undecylenyl-L-leucine (L-SUL), were also used in this study, and the

80 his study were sodium N-undecylenyl-L-valine-L-leucine (L-SUVL), and sodium N-undecylenyl-L-leucine-L

81 gh over other amino acids, such as L-serine, L-leucine, L-aspartic acid, L-glutamic acid, histamine,

82 transport rates for L-serine, L-citrulline, L-leucine, L-cystine or 2-deoxyglucose.

83 ormamide (DMF), methyl salicylate, caffeine, l-leucine, l-histidine, loratadine, ibuprofen, acetamino

84 ontaining 0.03-24% L-threonine, D-threonine, L-leucine, L-lysine, L-glutamic acid, or diglycine with

85 Uptake of tritiated thymidine, L-leucine, L-methionine and FDG into two human tumor cel

86 o tumor cells of several tracers (thymidine, L-leucine, L-methionine and FDG) in the presence of eith

87 ctants, the polymers of sodium N-undecylenyl-L-leucine-L-leucine (L-SULL), sodium N-undecylenyl-L-val

88 L-leucine (L-SUVL), and sodium N-undecylenyl-L-leucine-L-valine (L-SULV).

89 ogue, identified N-(1-deoxy-D-lactulos-1-yl)-L-leucine (Lac-L-Leu), N-(1-deoxy-D-fructos-1-yl)-D-leuc

90 ized using the lysosomotropic agent L-leucyl-L-leucine methyl ester (Leu-Leu-OMe).

91 Killing monocytes with l-leucine methyl ester abolished these T cell-monocyte c

92 abilization by lysosomotropic agent l-leucyl-l-leucine methyl ester that allows cytosolic release of

93 -l-valine, and a dipeptide, N-acetyl-l-valyl-l-leucine (N-Ac-VL), were studied via one- and two-dimen

94 pA1-575 can be covalently aminoacylated with l-leucine on the peptidyl carrier protein 1 domain.

95 and stimulation of the mTOR pathway through l-leucine or its metabolite alpha-KIC can partially resc

96 detected for the larger CepA constructs with l-leucine or other expected amino acid substrates, sugge

97 rameters kcat and K(m) for the hydrolysis of L-leucine p-nitroanilide (L-pNA) revealed a change in an

98 with A (alanine), D (aspartate), K (lysine), L (leucine), P (proline), and W (tryptophan).

99 The hydrolysis of L-leucine-p-nitroanilide was measured spectrophotometric

100 l-leucine partly rescued protein synthesis and rRNA prod

101 b) WPH; (c) L-isoleucine; (d) L-leucine; (e) L-leucine plus L-isoleucine; (f) L-isoleucyl-L-leucine d

102 sin of N-(4-methoxyphenylazoformyl)-L-leucyl-L-leucine plus some congeneric peptides provides a highl

103 amino-acid transporters, but a single System L ('leucine-preferring system') transporter, Slc7a5, med

104 mine with the acid chloride of N(alpha)-Fmoc-L-leucine provided a N(alpha)-Fmoc-N-(benzoyloxy)-L-leuc

105 ic labeling with deuterated (isopropyl-d(7))-L-leucine revealed that the isopropyl carbons give rise

106 Administration of L-leucine significantly improved the anemia in Rps19-def

107 l-leucine stimulation of the mTOR pathway partially resc

108 Polysodium N-undecenoxycarbonyl-L-leucine sulfate (poly-L-SUCLS) and polysodium N-undece

109 The polysodium N-undecenoyl-l-leucine sulfate shows distinct tubular structure, whil

110 ctivation of the mTOR pathway in response to L-leucine supplementation was retained, suggesting a pos

111 ic amino acid residue L-4-methylproline from L-leucine, support the involvement of this cluster in no

112 ic amino acid residue L-4-methylproline from L-leucine, support the involvement of this gene cluster

113 yl acrylate and an imino ester prepared from l-leucine t-butyl ester hydrochloride and 2-thiazolecarb

114 et is synthesized in seven linear steps from l-leucine t-butyl ester hydrochloride with all three iso

115 ubject to slow-onset, feedback inhibition by l-leucine, the first instance of an allosteric regulator

116 Binding of L-leucine to an enzyme variant (Y410F) that is kinetical

117 y of fetal arterial boluses of L-alanine and L-leucine to stimulate release of amino acids from the p

118 mbin, and angiotensin II likewise stimulated L-leucine transport by inducing LAT1 expression.

119 Treatment of SMCs with PDGF stimulated L-leucine transport in a concentration- and time-depende

120 act with the large neutral amino acid system L (leucine) transporter.

121 Concomitantly, l-leucine treatment partially improved cohesinopathy emb

122 we have validated the therapeutic effect of L-leucine using our recently generated mouse model for R

123 In the EDL, incubation with 100 or 200 mumol/l leucine versus no added leucine suppressed the activit

124 When 13.1 g/L leucine was added at 2-h intervals (from 0 to 22 h, 12

125 ectivity (alpha) and resolution (R(s)) for D,L-leucine were 1.16 and 1.64, respectively.

126 o identified a marker of nutritional status, l-leucine, which lowers the progesterone threshold, indi

127 and the statine moiety can be replaced with L-leucine while retaining anti-HIV activity.

128 Transamination of L-leucine with alpha-ketoglutarate results in formation

129 rom acetate, L-phenylalanine, L-cysteine and L-leucine with trichloroleucine as a direct precursor by

130 the two nuclear receptor-interacting LXXLL (L, leucine; X, any amino acid) motifs in PBP in a ligand